These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

4406 related items for PubMed ID: 23973703

  • 1. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D, Pöss J, Böhm M, Laufs U.
    J Am Coll Cardiol; 2013 Oct 15; 62(16):1401-8. PubMed ID: 23973703
    [Abstract] [Full Text] [Related]

  • 2. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
    Bergeron N, Phan BA, Ding Y, Fong A, Krauss RM.
    Circulation; 2015 Oct 27; 132(17):1648-66. PubMed ID: 26503748
    [Abstract] [Full Text] [Related]

  • 3. PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels.
    Marais AD, Kim JB, Wasserman SM, Lambert G.
    Pharmacol Ther; 2015 Jan 27; 145():58-66. PubMed ID: 25046268
    [Abstract] [Full Text] [Related]

  • 4. On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects.
    Tavori H, Rashid S, Fazio S.
    Atherosclerosis; 2015 Feb 27; 238(2):264-70. PubMed ID: 25544176
    [Abstract] [Full Text] [Related]

  • 5. Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).
    Schulz R, Schlüter KD, Laufs U.
    Basic Res Cardiol; 2015 Mar 27; 110(2):4. PubMed ID: 25600226
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo.
    Schiele F, Park J, Redemann N, Luippold G, Nar H.
    J Mol Biol; 2014 Feb 20; 426(4):843-52. PubMed ID: 24252255
    [Abstract] [Full Text] [Related]

  • 9. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A, Watts GF.
    Clin Ther; 2013 Aug 20; 35(8):1082-98. PubMed ID: 23932550
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibitors].
    Avci A, Demir K, Altunkeser BB.
    Turk Kardiyol Dern Ars; 2014 Oct 20; 42 Suppl 2():56-67. PubMed ID: 25693363
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K, Sharma M, Ferdinand KC.
    Nutr Metab Cardiovasc Dis; 2016 Oct 20; 26(10):853-62. PubMed ID: 27352986
    [Abstract] [Full Text] [Related]

  • 14. The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors.
    Shen L, Peng H, Xu D, Zhao S.
    Pharmacol Res; 2013 Jul 20; 73():27-34. PubMed ID: 23578522
    [Abstract] [Full Text] [Related]

  • 15. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels.
    Ferri N, Tibolla G, Pirillo A, Cipollone F, Mezzetti A, Pacia S, Corsini A, Catapano AL.
    Atherosclerosis; 2012 Feb 20; 220(2):381-6. PubMed ID: 22176652
    [Abstract] [Full Text] [Related]

  • 16. LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153-421): design, synthesis and biochemical evaluation.
    Alghamdi RH, O'Reilly P, Lu C, Gomes J, Lagace TA, Basak A.
    Eur J Med Chem; 2015 Mar 06; 92():890-907. PubMed ID: 25679794
    [Abstract] [Full Text] [Related]

  • 17. PCSK9 and its modulation.
    Cui CJ, Li S, Li JJ.
    Clin Chim Acta; 2015 Feb 02; 440():79-86. PubMed ID: 25444750
    [Abstract] [Full Text] [Related]

  • 18. Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition.
    Tibolla G, Norata GD, Artali R, Meneghetti F, Catapano AL.
    Nutr Metab Cardiovasc Dis; 2011 Nov 02; 21(11):835-43. PubMed ID: 21943799
    [Abstract] [Full Text] [Related]

  • 19. β-Estradiol results in a proprotein convertase subtilisin/kexin type 9-dependent increase in low-density lipoprotein receptor levels in human hepatic HuH7 cells.
    Starr AE, Lemieux V, Noad J, Moore JI, Dewpura T, Raymond A, Chrétien M, Figeys D, Mayne J.
    FEBS J; 2015 Jul 02; 282(14):2682-96. PubMed ID: 25913303
    [Abstract] [Full Text] [Related]

  • 20. An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes.
    Zhang L, McCabe T, Condra JH, Ni YG, Peterson LB, Wang W, Strack AM, Wang F, Pandit S, Hammond H, Wood D, Lewis D, Rosa R, Mendoza V, Cumiskey AM, Johns DG, Hansen BC, Shen X, Geoghagen N, Jensen K, Zhu L, Wietecha K, Wisniewski D, Huang L, Zhao JZ, Ernst R, Hampton R, Haytko P, Ansbro F, Chilewski S, Chin J, Mitnaul LJ, Pellacani A, Sparrow CP, An Z, Strohl W, Hubbard B, Plump AS, Blom D, Sitlani A.
    Int J Biol Sci; 2012 Jul 02; 8(3):310-27. PubMed ID: 22355267
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 221.